Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET) |
| |
| Affiliation: | 1. Paediatric Hematology Oncology Unit, “Policlinico-Giovanni XXII” Hospital, University of Bari, Italy;2. Pediatric Immunology Unit “Anna Meyer” Hospital University of Florence, Italy;3. Department of Clinical and Experimental Sciences, University of Brescia, Italy;4. Department of Translational Medical Sciences, Pediatric section, Federico II University, Naples, Italy;5. Paediatric Allergology and Immunology Unit, Policlinico Tor Vergata, University of Rome Tor, Vergata, Italy;6. Department of Molecular Medicine, Sapienza University of Rome, Italy;1. Unit of Epidemiology, Bambino Gesù Children''s Hospital IRCCS, Rome, Italy;2. International Centre on Birth Defects and Prematurity, Rome, Italy;3. Regional Health Agency of Lazio, Rome, Italy;4. Maternal and Child Health Institute, Marche University and Salesi Hospital, Ancona, Italy;5. Neonatal Intensive Care Unit, S. Maria della Misericordia University Hospital, Udine, Italy;6. Neonatal Intensive Care Unit, Burlo Garofolo Maternal and Child Health Institute, IRCCS, Trieste, Italy;7. Neonatal Intensive Care Unit, Pugliese-Ciaccio Hospital, Catanzaro, Italy;8. Unit of Epidemiology, Anna Meyer Children''s University Hospital and Regional Agency for Health of Tuscany, Florence, Italy;1. Division of Clinical Immunology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY;2. Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY;1. National Taiwan University College of Medicine, Taipei 10051, Taiwan;2. Chinese Medical Advancement Foundation, Taipei 10041, Taiwan;3. School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan;4. National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei 11221, Taiwan;5. Department of Chinese Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan;6. School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien 97004, Taiwan;1. Immunodeficiency Unit and Immunological Diagnostics Laboratory, Dr. von Hauner Children''s Hospital, Ludwig-Maximilians-Universität, Munich, Germany;2. Research Unit Pediatric Hematology and Immunology, Division of Pediatric Hematology-Oncology, Department of Pediatrics and Adolescent Medicine, Medical University Graz, Graz, Austria;1. Centre de Référence Déficits Immunitaires Héréditaires (CEREDIH), Hôpital Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France;2. Unité d''Immuno-Hématologie et Rhumatologie pédiatrique, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France;3. Paris Descartes–Sorbonne Paris Cité University, Imagine Institute, Paris, France;4. INSERM UMR 1163, Paris, France;5. Collège de France, Paris, France;6. Université Paris Descartes, INSERM UMRS 1138 Team 22, Paris, France AP-HP, Hôpital Necker Enfants Malades, Biostatistics Unit, Paris, France;7. Laboratory of Human Genetics of Infectious Diseases, INSERM UMR 1163, Paris, France |
| |
| Abstract: | Infectious complications are a major cause of morbidity and mortality in patients with primary or secondary immunodeficiency. Prevention of infectious diseases by vaccines is among the most effective healthcare measures mainly for these subjects. However immunocompromised people vary in their degree of immunosuppression and susceptibility to infection and, therefore, represent a heterogeneous population with regard to immunization. To date there is no well- established evidence for use of vaccines in immunodeficient patients, and indications are not clearly defined even in high-quality reviews and in most of the guidelines prepared to provide recommendations for the active vaccination of immunocompromised hosts. The aim of this document is to issue recommendations based on published literature and the collective experience of the Italian primary immunodeficiency centers, about how and when vaccines can be used in immunocompromised patients, in order to facilitate physician decisions and to ensure the best immune protection with the lowest risk to the health of the patient. |
| |
| Keywords: | Vaccination Primary immunodeficiency Syndromic immunodeficiency Secondary immunodeficiency |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
